143 related articles for article (PubMed ID: 19346126)
1. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
Ling YH; Aracil M; Jimeno J; Perez-Soler R; Zou Y
Eur J Cancer; 2009 Jul; 45(10):1855-64. PubMed ID: 19346126
[TBL] [Abstract][Full Text] [Related]
2. PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase.
Ling YH; Aracil M; Zou Y; Yuan Z; Lu B; Jimeno J; Cuervo AM; Perez-Soler R
Clin Cancer Res; 2011 Aug; 17(16):5353-66. PubMed ID: 21690574
[TBL] [Abstract][Full Text] [Related]
3. ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
Teixidó C; Arguelaguet E; Pons B; Aracil M; Jimeno J; Somoza R; Marés R; Ramón Y Cajal S; Hernández-Losa J
Int J Oncol; 2012 Jul; 41(1):317-24. PubMed ID: 22485250
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
5. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
[TBL] [Abstract][Full Text] [Related]
6. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound.
Serova M; de Gramont A; Bieche I; Riveiro ME; Galmarini CM; Aracil M; Jimeno J; Faivre S; Raymond E
Mar Drugs; 2013 Mar; 11(3):944-59. PubMed ID: 23519149
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
Tsai AC; Pai HC; Wang CY; Liou JP; Teng CM; Wang JC; Pan SL
Br J Pharmacol; 2014 Jan; 171(1):122-33. PubMed ID: 24116948
[TBL] [Abstract][Full Text] [Related]
9. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
[TBL] [Abstract][Full Text] [Related]
11. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
12. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
13. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
Xu L; Meng X; Xu N; Fu W; Tan H; Zhang L; Zhou Q; Qian J; Tu S; Li X; Lao Y; Xu H
Cell Death Dis; 2018 Feb; 9(3):262. PubMed ID: 29449529
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib: a new therapeutic approach for non-small cell lung cancer.
Bonomi P
Expert Opin Investig Drugs; 2003 Aug; 12(8):1395-401. PubMed ID: 12882624
[TBL] [Abstract][Full Text] [Related]
15. Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors.
Goel S; Viteri S; Morán T; Coronado C; Dios JL; Miguel-Lillo B; Fernández-García EM; Rosell R
Invest New Drugs; 2016 Feb; 34(1):75-83. PubMed ID: 26627080
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.
Wu Q; Li MY; Li HQ; Deng CH; Li L; Zhou TY; Lu W
Acta Pharmacol Sin; 2013 Nov; 34(11):1427-36. PubMed ID: 24096601
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.
Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH
Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
Zhang W; Peyton M; Xie Y; Soh J; Minna JD; Gazdar AF; Frenkel EP
J Thorac Oncol; 2009 Feb; 4(2):161-6. PubMed ID: 19179890
[TBL] [Abstract][Full Text] [Related]
19. Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
Rice JW; Veal JM; Barabasz A; Foley B; Fadden P; Scott A; Huang K; Steed P; Hall S
Oncol Res; 2009; 18(5-6):229-42. PubMed ID: 20225761
[TBL] [Abstract][Full Text] [Related]
20. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
